Financials data is unavailable for this security.
View more
Year on year ADC Therapeutics SA 's revenues fell -66.86% from 209.91m to 69.56m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 157.13m to a larger loss of 240.05m.
Gross margin | 92.99% |
---|---|
Net profit margin | -312.84% |
Operating margin | -206.87% |
Return on assets | -47.51% |
---|---|
Return on equity | -- |
Return on investment | -56.37% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at ADC Therapeutics SA fell by 47.84m. Cash Flow from Financing totalled 73.88m or 106.21% of revenues. In addition the company used 118.69m for operations while cash used for investing totalled 3.22m.
Cash flow per share | -2.43 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -1.36 |
---|---|
Tangible book value per share | -1.36 |
More ▼
Balance sheet in USDView more
Current ratio | 6.17 |
---|---|
Quick ratio | 5.90 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.44 |
More ▼